B2RLaw, working with Pillsbury Winthrop Shaw Pittman, has advised Neuca and Humaneva on the sale of a minority stake in Humaneva to Viking Global Investors for USD 50 million. Clifford Chance advised Viking Global Investors.
Humaneva is the parent company of Pratia, Kapadi, and Hyggio, all of which are integrated clinical trial solutions.
According to B2RLaw, “the transaction will contribute to the implementation of the long-term strategy in the area of clinical research and is a key step in strengthening the group’s position in the international biotechnology arena.”
“Partnering with Viking is a strategic milestone for us,” commented Humaneva CEO Tomasz Dabrowski. “Viking’s unique blend of hedge fund and private equity expertise, coupled with their long-term, value-building perspective, aligns perfectly with Humaneva’s vision.”
“Cooperation with our new partner may result in prospective new contacts and greater trust in our company from the US market players,” added Neuca Vice President of the Board of Directors Grzegorz Dzik. “This transaction is also proof of the high potential of this area and thus of the long-term prospects of the group as well as the credibility of our activities and confirms the correctness of the growth trajectory for the segment pursued so far.”
In 2023, B2RLaw advised Moffitt Cancer Center and OncoBay Clinical on Clinscience PLN 150 million investment in OncoBay (as reported by CEE Legal Matters on February 28, 2023).
The B2RLaw team included Senior Partner Rafal Stroinski and Associates Magdalena Borychowska, Danyila Zubach, Konrad Czernecki, and Konrad Zajac.
The Clifford Chance team in Warsaw included Partner Wojciech Polz, Counsels Tomasz Derda, Krzysztof Hajdamowicz, and Tomasz Szymura, Senior Associate Arkadiusz Walkowicz, and Attorney at Law Marta Michalek-Gervais.
